Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026): By Type, Drug Class, Route of Administration, Distribution Channel and Region

Global Arthritis Therapeutic Market is expected to reach US$ 35.46 Bn. at a CAGR of 4.6 during the forecast period 2026. Global Arthritis Therapeutics Market To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

Global Arthritis Therapeutic Market Drivers and Restrains

The significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients. Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation Analysis

By Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional Analysis

The Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region. The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investor’s guide.

Scope of the Global Arthritis Therapeutic Market: Inquire before buying

Global Arthritis Therapeutic Market, by Type

• Psoriatic Arthritis • Rheumatoid Arthritis • Osteoarthritis • Gout • Others

Global Arthritis Therapeutic Market, by Drug Class

• TNF Inhibitors • Interleukin Inhibitors • NSAIDs • Corticosteroids • Xanthine Oxidase Inhibitors • Others

Global Arthritis Therapeutic Market by Route of Administration

• Oral • Parenteral • Topical

Global Arthritis Therapeutic Market, by Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Global Arthritis Therapeutic Market, by Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Global Arthritis Therapeutic Market, Major Players

• Pfizer Inc. • Bristol Myers Squibb • Abbvie Inc. • Astrazeneca Pharma • Ucb Pharma • Genentech • Janssen Pharmaceutical • Immunex Corp. • Medac Pharma • Boehringer Ingelheim • Novartis, Biogen • Eli Lilly And Company • Astellas Pharma • Mallinckrodt • Roche • Vertex Pharmaceutical • Amgen, Inc. • Merck & Co., Inc. • F. Hoffmann-La Roche Ltd • Sanofi • Celgene Corporation • Gilead Sciences, Inc.
Global Arthritis Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Arthritis Therapeutic Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Arthritis Therapeutic Market Analysis and Forecast 6.1. Global Arthritis Therapeutic Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Arthritis Therapeutic Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Arthritis Therapeutic Market Value Share Analysis, by Type 7.4. Global Arthritis Therapeutic Market Size (US$ Bn) Forecast, by Type 7.5. Global Arthritis Therapeutic Market Analysis, by Type 7.6. Global Arthritis Therapeutic Market Attractiveness Analysis, by Type 8. Global Arthritis Therapeutic Market Analysis and Forecast, by Drug Class 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Arthritis Therapeutic Market Value Share Analysis, by Drug Class 8.4. Global Arthritis Therapeutic Market Size (US$ Bn) Forecast, by Drug Class 8.5. Global Arthritis Therapeutic Market Analysis, by Drug Class 8.6. Global Arthritis Therapeutic Market Attractiveness Analysis, by Drug Class 9. Global Arthritis Therapeutic Market Analysis and Forecast, by Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 9.4. Global Arthritis Therapeutic Market Size (US$ Bn) Forecast, by Route of Administration 9.5. Global Arthritis Therapeutic Market Analysis, by Route of Administration 9.6. Global Arthritis Therapeutic Market Attractiveness Analysis, by Route of Administration 10. Global Arthritis Therapeutic Market Analysis and Forecast, by Distribution Channel 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 10.4. Global Arthritis Therapeutic Market Size (US$ Bn) Forecast, by Distribution Channel 10.5. Global Arthritis Therapeutic Market Analysis, by Distribution Channel 10.6. Global Arthritis Therapeutic Market Attractiveness Analysis, by Distribution Channel 11. Global Arthritis Therapeutic Market Analysis, by Region 11.1. Global Arthritis Therapeutic Market Value Share Analysis, by Region 11.2. Global Arthritis Therapeutic Market Size (US$ Bn) Forecast, by Region 11.3. Global Arthritis Therapeutic Market Attractiveness Analysis, by Region 12. North America Arthritis Therapeutic Market Analysis 12.1. Key Findings 12.2. North America Arthritis Therapeutic Market Overview 12.3. North America Arthritis Therapeutic Market Value Share Analysis, by Type 12.4. North America Arthritis Therapeutic Market Forecast, by Type 12.4.1. Psoriatic Arthritis 12.4.2. Rheumatoid Arthritis 12.4.3. Osteoarthritis 12.4.4. Gout 12.4.5. Others 12.5. North America Arthritis Therapeutic Market Value Share Analysis, by Drug Class 12.6. North America Arthritis Therapeutic Market Forecast, by Drug Class 12.6.1. TNF Inhibitors 12.6.2. Interleukin Inhibitors 12.6.3. NSAIDs 12.6.4. Corticosteroids 12.6.5. Xanthine Oxidase Inhibitors 12.6.6. Others 12.7. North America Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 12.8. North America Arthritis Therapeutic Market Forecast, by Route of Administration 12.8.1. Oral 12.8.2. Parenteral 12.8.3. Topical 12.9. North America Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 12.10. North America Arthritis Therapeutic Market Forecast, by Distribution Channel 12.10.1.1. Hospital Pharmacies 12.10.1.2. Retail Pharmacies 12.10.1.3. Others 12.11. North America Arthritis Therapeutic Market Value Share Analysis, by Country 12.12. North America Arthritis Therapeutic Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Arthritis Therapeutic Market Analysis, by Country 12.14. U.S. Arthritis Therapeutic Market Forecast, by Type 12.14.1. Psoriatic Arthritis 12.14.2. Rheumatoid Arthritis 12.14.3. Osteoarthritis 12.14.4. Gout 12.14.5. Others 12.15. U.S. Arthritis Therapeutic Market Forecast, by Drug Class 12.15.1. TNF Inhibitors 12.15.2. Interleukin Inhibitors 12.15.3. NSAIDs 12.15.4. Corticosteroids 12.15.5. Xanthine Oxidase Inhibitors 12.15.6. Others 12.16. U.S. Arthritis Therapeutic Market Forecast, by Route of Administration 12.16.1. Oral 12.16.2. Parenteral 12.16.3. Topical 12.17. U.S. Arthritis Therapeutic Market Forecast, by Distribution Channel 12.17.1.1. Hospital Pharmacies 12.17.1.2. Retail Pharmacies 12.17.1.3. Others 12.18. Canada Arthritis Therapeutic Market Forecast, by Type 12.18.1. Psoriatic Arthritis 12.18.2. Rheumatoid Arthritis 12.18.3. Osteoarthritis 12.18.4. Gout 12.18.5. Others 12.19. Canada Arthritis Therapeutic Market Forecast, by Drug Class 12.19.1. TNF Inhibitors 12.19.2. Interleukin Inhibitors 12.19.3. NSAIDs 12.19.4. Corticosteroids 12.19.5. Xanthine Oxidase Inhibitors 12.19.6. Others 12.20. Canada Arthritis Therapeutic Market Forecast, by Route of Administration 12.20.1. Oral 12.20.2. Parenteral 12.20.3. Topical 12.21. Canada Arthritis Therapeutic Market Forecast, by Distribution Channel 12.21.1.1. Hospital Pharmacies 12.21.1.2. Retail Pharmacies 12.21.1.3. Others 12.22. North America Arthritis Therapeutic Market Attractiveness Analysis 12.22.1. By Type 12.22.2. By Drug Class 12.22.3. By Route of Administration 12.22.4. By Distribution Channel 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Arthritis Therapeutic Market Analysis 13.1. Key Findings 13.2. Europe Arthritis Therapeutic Market Overview 13.3. Europe Arthritis Therapeutic Market Value Share Analysis, by Type 13.4. Europe Arthritis Therapeutic Market Forecast, by Type 13.4.1. Psoriatic Arthritis 13.4.2. Rheumatoid Arthritis 13.4.3. Osteoarthritis 13.4.4. Gout 13.4.5. Others 13.5. Europe Arthritis Therapeutic Market Value Share Analysis, by Drug Class 13.6. Europe Arthritis Therapeutic Market Forecast, by Drug Class 13.6.1. TNF Inhibitors 13.6.2. Interleukin Inhibitors 13.6.3. NSAIDs 13.6.4. Corticosteroids 13.6.5. Xanthine Oxidase Inhibitors 13.6.6. Others 13.7. Europe Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 13.8. Europe Arthritis Therapeutic Market Forecast, by Route of Administration 13.8.1. Oral 13.8.2. Parenteral 13.8.3. Topical 13.9. Europe Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 13.10. Europe Arthritis Therapeutic Market Forecast, by Distribution Channel 13.10.1.1. Hospital Pharmacies 13.10.1.2. Retail Pharmacies 13.10.1.3. Others 13.11. Europe Arthritis Therapeutic Market Value Share Analysis, by Country 13.12. Europe Arthritis Therapeutic Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Arthritis Therapeutic Market Analysis, by Country 13.14. Germany Arthritis Therapeutic Market Forecast, by Type 13.14.1. Psoriatic Arthritis 13.14.2. Rheumatoid Arthritis 13.14.3. Osteoarthritis 13.14.4. Gout 13.14.5. Others 13.15. Germany Arthritis Therapeutic Market Forecast, by Drug Class 13.15.1. TNF Inhibitors 13.15.2. Interleukin Inhibitors 13.15.3. NSAIDs 13.15.4. Corticosteroids 13.15.5. Xanthine Oxidase Inhibitors 13.15.6. Others 13.16. Germany Arthritis Therapeutic Market Forecast, by Route of Administration 13.16.1. Oral 13.16.2. Parenteral 13.16.3. Topical 13.17. Germany Arthritis Therapeutic Market Forecast, by Distribution Channel 13.17.1.1. Hospital Pharmacies 13.17.1.2. Retail Pharmacies 13.17.1.3. Others 13.18. U.K. Arthritis Therapeutic Market Forecast, by Type 13.18.1. Psoriatic Arthritis 13.18.2. Rheumatoid Arthritis 13.18.3. Osteoarthritis 13.18.4. Gout 13.18.5. Others 13.19. U.K. Arthritis Therapeutic Market Forecast, by Drug Class 13.19.1. TNF Inhibitors 13.19.2. Interleukin Inhibitors 13.19.3. NSAIDs 13.19.4. Corticosteroids 13.19.5. Xanthine Oxidase Inhibitors 13.19.6. Others 13.20. U.K. Arthritis Therapeutic Market Forecast, by Route of Administration 13.20.1. Oral 13.20.2. Parenteral 13.20.3. Topical 13.21. U.K. Arthritis Therapeutic Market Forecast, by Distribution Channel 13.21.1. Hospital Pharmacies 13.21.2. Retail Pharmacies 13.21.3. Others 13.22. France Arthritis Therapeutic Market Forecast, by Type 13.22.1. Psoriatic Arthritis 13.22.2. Rheumatoid Arthritis 13.22.3. Osteoarthritis 13.22.4. Gout 13.22.5. Others 13.23. France Arthritis Therapeutic Market Forecast, by Drug Class 13.23.1. TNF Inhibitors 13.23.2. Interleukin Inhibitors 13.23.3. NSAIDs 13.23.4. Corticosteroids 13.23.5. Xanthine Oxidase Inhibitors 13.23.6. Others 13.24. France Arthritis Therapeutic Market Forecast, by Route of Administration 13.24.1. Oral 13.24.2. Parenteral 13.24.3. Topical 13.25. France Arthritis Therapeutic Market Forecast, by Distribution Channel 13.25.1.1. Hospital Pharmacies 13.25.1.2. Retail Pharmacies 13.25.1.3. Others 13.26. Italy Arthritis Therapeutic Market Forecast, by Type 13.26.1. Psoriatic Arthritis 13.26.2. Rheumatoid Arthritis 13.26.3. Osteoarthritis 13.26.4. Gout 13.26.5. Others 13.27. Italy Arthritis Therapeutic Market Forecast, by Drug Class 13.27.1. TNF Inhibitors 13.27.2. Interleukin Inhibitors 13.27.3. NSAIDs 13.27.4. Corticosteroids 13.27.5. Xanthine Oxidase Inhibitors 13.27.6. Others 13.28. Italy Arthritis Therapeutic Market Forecast, by Route of Administration 13.28.1. Oral 13.28.2. Parenteral 13.28.3. Topical 13.29. Italy Arthritis Therapeutic Market Forecast, by Distribution Channel 13.29.1.1. Hospital Pharmacies 13.29.1.2. Retail Pharmacies 13.29.1.3. Others 13.30. Spain Arthritis Therapeutic Market Forecast, by Type 13.30.1. Psoriatic Arthritis 13.30.2. Rheumatoid Arthritis 13.30.3. Osteoarthritis 13.30.4. Gout 13.30.5. Others 13.31. Spain Arthritis Therapeutic Market Forecast, by Drug Class 13.31.1. TNF Inhibitors 13.31.2. Interleukin Inhibitors 13.31.3. NSAIDs 13.31.4. Corticosteroids 13.31.5. Xanthine Oxidase Inhibitors 13.31.6. Others 13.32. Spain Arthritis Therapeutic Market Forecast, by Route of Administration 13.32.1. Oral 13.32.2. Parenteral 13.32.3. Topical 13.33. Spain Arthritis Therapeutic Market Forecast, by Distribution Channel 13.33.1.1. Hospital Pharmacies 13.33.1.2. Retail Pharmacies 13.33.1.3. Others 13.34. Rest of Europe Arthritis Therapeutic Market Forecast, by Type 13.34.1. Psoriatic Arthritis 13.34.2. Rheumatoid Arthritis 13.34.3. Osteoarthritis 13.34.4. Gout 13.34.5. Others 13.35. Rest of Europe Arthritis Therapeutic Market Forecast, by Drug Class 13.35.1. TNF Inhibitors 13.35.2. Interleukin Inhibitors 13.35.3. NSAIDs 13.35.4. Corticosteroids 13.35.5. Xanthine Oxidase Inhibitors 13.35.6. Others 13.36. Rest of Europe Arthritis Therapeutic Market Forecast, by Route of Administration 13.36.1. Oral 13.36.2. Parenteral 13.36.3. Topical 13.37. Rest Of Europe Arthritis Therapeutic Market Forecast, by Distribution Channel 13.37.1.1. Hospital Pharmacies 13.37.1.2. Retail Pharmacies 13.37.1.3. Others 13.38. Europe Arthritis Therapeutic Market Attractiveness Analysis 13.38.1. By Type 13.38.2. By Drug Class 13.38.3. By Route of Administration 13.38.4. By Distribution Channel 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Arthritis Therapeutic Market Analysis 14.1. Key Findings 14.2. Asia Pacific Arthritis Therapeutic Market Overview 14.3. Asia Pacific Arthritis Therapeutic Market Value Share Analysis, by Type 14.4. Asia Pacific Arthritis Therapeutic Market Forecast, by Type 14.4.1. Psoriatic Arthritis 14.4.2. Rheumatoid Arthritis 14.4.3. Osteoarthritis 14.4.4. Gout 14.4.5. Others 14.5. Asia Pacific Arthritis Therapeutic Market Value Share Analysis, by Drug Class 14.6. Asia Pacific Arthritis Therapeutic Market Forecast, by Drug Class 14.6.1. TNF Inhibitors 14.6.2. Interleukin Inhibitors 14.6.3. NSAIDs 14.6.4. Corticosteroids 14.6.5. Xanthine Oxidase Inhibitors 14.6.6. Others 14.7. Asia Pacific Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 14.8. Asia Pacific Arthritis Therapeutic Market Forecast, by Route of Administration 14.8.1. Oral 14.8.2. Parenteral 14.8.3. Topical 14.9. Asia Pacific Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 14.10. Asia Pacific Arthritis Therapeutic Market Forecast, by Distribution Channel 14.10.1.1. Hospital Pharmacies 14.10.1.2. Retail Pharmacies 14.10.1.3. Others 14.11. Asia Pacific Arthritis Therapeutic Market Value Share Analysis, by Country 14.12. Asia Pacific Arthritis Therapeutic Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Arthritis Therapeutic Market Analysis, by Country 14.14. China Arthritis Therapeutic Market Forecast, by Type 14.14.1. Psoriatic Arthritis 14.14.2. Rheumatoid Arthritis 14.14.3. Osteoarthritis 14.14.4. Gout 14.14.5. Others 14.15. China Arthritis Therapeutic Market Forecast, by Drug Class 14.15.1. TNF Inhibitors 14.15.2. Interleukin Inhibitors 14.15.3. NSAIDs 14.15.4. Corticosteroids 14.15.5. Xanthine Oxidase Inhibitors 14.15.6. Others 14.16. China Arthritis Therapeutic Market Forecast, by Route of Administration 14.16.1. Oral 14.16.2. Parenteral 14.16.3. Topical 14.17. China Arthritis Therapeutic Market Forecast, by Distribution Channel 14.17.1.1. Hospital Pharmacies 14.17.1.2. Retail Pharmacies 14.17.1.3. Others 14.18. India Arthritis Therapeutic Market Forecast, by Type 14.18.1. Psoriatic Arthritis 14.18.2. Rheumatoid Arthritis 14.18.3. Osteoarthritis 14.18.4. Gout 14.18.5. Others 14.19. India Arthritis Therapeutic Market Forecast, by Drug Class 14.19.1. TNF Inhibitors 14.19.2. Interleukin Inhibitors 14.19.3. NSAIDs 14.19.4. Corticosteroids 14.19.5. Xanthine Oxidase Inhibitors 14.19.6. Others 14.20. India Arthritis Therapeutic Market Forecast, by Route of Administration 14.20.1. Oral 14.20.2. Parenteral 14.20.3. Topical 14.21. India Arthritis Therapeutic Market Forecast, by Distribution Channel 14.21.1.1. Hospital Pharmacies 14.21.1.2. Retail Pharmacies 14.21.1.3. Others 14.22. Japan Arthritis Therapeutic Market Forecast, by Type 14.22.1. Psoriatic Arthritis 14.22.2. Rheumatoid Arthritis 14.22.3. Osteoarthritis 14.22.4. Gout 14.22.5. Others 14.23. Japan Arthritis Therapeutic Market Forecast, by Drug Class 14.23.1. TNF Inhibitors 14.23.2. Interleukin Inhibitors 14.23.3. NSAIDs 14.23.4. Corticosteroids 14.23.5. Xanthine Oxidase Inhibitors 14.23.6. Others 14.24. Japan Arthritis Therapeutic Market Forecast, by Route of Administration 14.24.1. Oral 14.24.2. Parenteral 14.24.3. Topical 14.25. Japan Arthritis Therapeutic Market Forecast, by Distribution Channel 14.25.1.1. Hospital Pharmacies 14.25.1.2. Retail Pharmacies 14.25.1.3. Others 14.26. ASEAN Arthritis Therapeutic Market Forecast, by Type 14.26.1. Psoriatic Arthritis 14.26.2. Rheumatoid Arthritis 14.26.3. Osteoarthritis 14.26.4. Gout 14.26.5. Others 14.27. ASEAN Arthritis Therapeutic Market Forecast, by Drug Class 14.27.1. TNF Inhibitors 14.27.2. Interleukin Inhibitors 14.27.3. NSAIDs 14.27.4. Corticosteroids 14.27.5. Xanthine Oxidase Inhibitors 14.27.6. Others 14.28. ASEAN Arthritis Therapeutic Market Forecast, by Route of Administration 14.28.1. Oral 14.28.2. Parenteral 14.28.3. Topical 14.29. ASEAN Arthritis Therapeutic Market Forecast, by Distribution Channel 14.29.1.1. Hospital Pharmacies 14.29.1.2. Retail Pharmacies 14.29.1.3. Others 14.30. Rest of Asia Pacific Arthritis Therapeutic Market Forecast, by Type 14.30.1. Psoriatic Arthritis 14.30.2. Rheumatoid Arthritis 14.30.3. Osteoarthritis 14.30.4. Gout 14.30.5. Others 14.31. Rest of Asia Pacific Arthritis Therapeutic Market Forecast, by Drug Class 14.31.1. TNF Inhibitors 14.31.2. Interleukin Inhibitors 14.31.3. NSAIDs 14.31.4. Corticosteroids 14.31.5. Xanthine Oxidase Inhibitors 14.31.6. Others 14.32. Rest of Asia Pacific Arthritis Therapeutic Market Forecast, by Route of Administration 14.32.1. Oral 14.32.2. Parenteral 14.32.3. Topical 14.33. Rest of Asia Pacific Arthritis Therapeutic Market Forecast, by Distribution Channel 14.33.1.1. Hospital Pharmacies 14.33.1.2. Retail Pharmacies 14.33.1.3. Others 14.34. Asia Pacific Arthritis Therapeutic Market Attractiveness Analysis 14.34.1. By Type 14.34.2. By Drug Class 14.34.3. By Route of Administration 14.34.4. By Distribution Channel 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Arthritis Therapeutic Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Arthritis Therapeutic Market Overview 15.3. Middle East & Africa Arthritis Therapeutic Market Value Share Analysis, by Type 15.4. Middle East & Africa Arthritis Therapeutic Market Forecast, by Type 15.4.1. Psoriatic Arthritis 15.4.2. Rheumatoid Arthritis 15.4.3. Osteoarthritis 15.4.4. Gout 15.4.5. Others 15.5. Middle East & Africa Arthritis Therapeutic Market Value Share Analysis, by Drug Class 15.6. Middle East & Africa Arthritis Therapeutic Market Forecast, by Drug Class 15.6.1. TNF Inhibitors 15.6.2. Interleukin Inhibitors 15.6.3. NSAIDs 15.6.4. Corticosteroids 15.6.5. Xanthine Oxidase Inhibitors 15.6.6. Others 15.7. Middle East & Africa Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 15.8. Middle East & Africa Arthritis Therapeutic Market Forecast, by Route of Administration 15.8.1. Oral 15.8.2. Parenteral 15.8.3. Topical 15.9. Middle East & Africa Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 15.10. Middle East & Africa Arthritis Therapeutic Market Forecast, by Distribution Channel 15.10.1.1. Hospital Pharmacies 15.10.1.2. Retail Pharmacies 15.10.1.3. Others 15.11. Middle East & Africa Arthritis Therapeutic Market Value Share Analysis, by Country 15.12. Middle East & Africa Arthritis Therapeutic Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Arthritis Therapeutic Market Analysis, by Country 15.14. GCC Arthritis Therapeutic Market Forecast, by Type 15.14.1. Psoriatic Arthritis 15.14.2. Rheumatoid Arthritis 15.14.3. Osteoarthritis 15.14.4. Gout 15.14.5. Others 15.15. GCC Arthritis Therapeutic Market Forecast, by Drug Class 15.15.1. TNF Inhibitors 15.15.2. Interleukin Inhibitors 15.15.3. NSAIDs 15.15.4. Corticosteroids 15.15.5. Xanthine Oxidase Inhibitors 15.15.6. Others 15.16. GCC Arthritis Therapeutic Market Forecast, by Route of Administration 15.16.1. Oral 15.16.2. Parenteral 15.16.3. Topical 15.17. GCC Arthritis Therapeutic Market Forecast, by Distribution Channel 15.17.1.1. Hospital Pharmacies 15.17.1.2. Retail Pharmacies 15.17.1.3. Others 15.18. South Africa Arthritis Therapeutic Market Forecast, by Type 15.18.1. Psoriatic Arthritis 15.18.2. Rheumatoid Arthritis 15.18.3. Osteoarthritis 15.18.4. Gout 15.18.5. Others 15.19. South Africa Arthritis Therapeutic Market Forecast, by Drug Class 15.19.1. TNF Inhibitors 15.19.2. Interleukin Inhibitors 15.19.3. NSAIDs 15.19.4. Corticosteroids 15.19.5. Xanthine Oxidase Inhibitors 15.19.6. Others 15.20. South Africa Arthritis Therapeutic Market Forecast, by Route of Administration 15.20.1. Oral 15.20.2. Parenteral 15.20.3. Topical 15.21. South Africa Arthritis Therapeutic Market Forecast, by Distribution Channel 15.21.1.1. Hospital Pharmacies 15.21.1.2. Retail Pharmacies 15.21.1.3. Others 15.22. Rest of Middle East & Africa Arthritis Therapeutic Market Forecast, by Type 15.22.1. Psoriatic Arthritis 15.22.2. Rheumatoid Arthritis 15.22.3. Osteoarthritis 15.22.4. Gout 15.22.5. Others 15.23. Rest of Middle East & Africa Arthritis Therapeutic Market Forecast, by Drug Class 15.23.1. TNF Inhibitors 15.23.2. Interleukin Inhibitors 15.23.3. NSAIDs 15.23.4. Corticosteroids 15.23.5. Xanthine Oxidase Inhibitors 15.23.6. Others 15.24. Rest of Middle East & Africa Arthritis Therapeutic Market Forecast, by Route of Administration 15.24.1. Oral 15.24.2. Parenteral 15.24.3. Topical 15.25. Rest of Middle East & Africa Arthritis Therapeutic Market Forecast, by Distribution Channel 15.25.1.1. Hospital Pharmacies 15.25.1.2. Retail Pharmacies 15.25.1.3. Others 15.26. Middle East & Africa Arthritis Therapeutic Market Attractiveness Analysis 15.26.1. By Type 15.26.2. By Drug Class 15.26.3. By Route of Administration 15.26.4. By Distribution Channel 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Arthritis Therapeutic Market Analysis 16.1. Key Findings 16.2. South America Arthritis Therapeutic Market Overview 16.3. South America Arthritis Therapeutic Market Value Share Analysis, by Type 16.4. South America Arthritis Therapeutic Market Forecast, by Type 16.4.1. Psoriatic Arthritis 16.4.2. Rheumatoid Arthritis 16.4.3. Osteoarthritis 16.4.4. Gout 16.4.5. Others 16.5. South America Arthritis Therapeutic Market Value Share Analysis, by Drug Class 16.6. South America Arthritis Therapeutic Market Forecast, by Drug Class 16.6.1. TNF Inhibitors 16.6.2. Interleukin Inhibitors 16.6.3. NSAIDs 16.6.4. Corticosteroids 16.6.5. Xanthine Oxidase Inhibitors 16.6.6. Others 16.7. South America Arthritis Therapeutic Market Value Share Analysis, by Route of Administration 16.8. South America Arthritis Therapeutic Market Forecast, by Route of Administration 16.8.1. Oral 16.8.2. Parenteral 16.8.3. Topical 16.9. South America Arthritis Therapeutic Market Value Share Analysis, by Distribution Channel 16.10. South America Arthritis Therapeutic Market Forecast, by Distribution Channel 16.10.1.1. Hospital Pharmacies 16.10.1.2. Retail Pharmacies 16.10.1.3. Others 16.11. South America Arthritis Therapeutic Market Value Share Analysis, by Country 16.12. South America Arthritis Therapeutic Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Arthritis Therapeutic Market Analysis, by Country 16.14. Brazil Arthritis Therapeutic Market Forecast, by Type 16.14.1. Psoriatic Arthritis 16.14.2. Rheumatoid Arthritis 16.14.3. Osteoarthritis 16.14.4. Gout 16.14.5. Others 16.15. Brazil Arthritis Therapeutic Market Forecast, by Drug Class 16.15.1. TNF Inhibitors 16.15.2. Interleukin Inhibitors 16.15.3. NSAIDs 16.15.4. Corticosteroids 16.15.5. Xanthine Oxidase Inhibitors 16.15.6. Others 16.16. Brazil Arthritis Therapeutic Market Forecast, by Route of Administration 16.16.1. Oral 16.16.2. Parenteral 16.16.3. Topical 16.17. Brazil Arthritis Therapeutic Market Forecast, by Distribution Channel 16.17.1.1. Hospital Pharmacies 16.17.1.2. Retail Pharmacies 16.17.1.3. Others 16.18. Mexico Arthritis Therapeutic Market Forecast, by Type 16.18.1. Psoriatic Arthritis 16.18.2. Rheumatoid Arthritis 16.18.3. Osteoarthritis 16.18.4. Gout 16.18.5. Others 16.19. Mexico Arthritis Therapeutic Market Forecast, by Drug Class 16.19.1. TNF Inhibitors 16.19.2. Interleukin Inhibitors 16.19.3. NSAIDs 16.19.4. Corticosteroids 16.19.5. Xanthine Oxidase Inhibitors 16.19.6. Others 16.20. Mexico Arthritis Therapeutic Market Forecast, by Route of Administration 16.20.1. Oral 16.20.2. Parenteral 16.20.3. Topical 16.21. Mexico Arthritis Therapeutic Market Forecast, by Distribution Channel 16.21.1.1. Hospital Pharmacies 16.21.1.2. Retail Pharmacies 16.21.1.3. Others 16.22. Rest of South America Arthritis Therapeutic Market Forecast, by Type 16.22.1. Psoriatic Arthritis 16.22.2. Rheumatoid Arthritis 16.22.3. Osteoarthritis 16.22.4. Gout 16.22.5. Others 16.23. Rest of South America Arthritis Therapeutic Market Forecast, by Drug Class 16.23.1. TNF Inhibitors 16.23.2. Interleukin Inhibitors 16.23.3. NSAIDs 16.23.4. Corticosteroids 16.23.5. Xanthine Oxidase Inhibitors 16.23.6. Others 16.24. Rest of South America Arthritis Therapeutic Market Forecast, by Route of Administration 16.24.1. Oral 16.24.2. Parenteral 16.24.3. Topical 16.25. Rest of South America Arthritis Therapeutic Market Forecast, by Distribution Channel 16.25.1.1. Hospital Pharmacies 16.25.1.2. Retail Pharmacies 16.25.1.3. Others 16.26. South America Arthritis Therapeutic Market Attractiveness Analysis 16.26.1. By Type 16.26.2. By Drug Class 16.26.3. By Route of Administration 16.26.4. By Distribution Channel 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Astrazeneca Pharma 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. Abbvie Inc. 17.3.3. Ucb Pharma 17.3.4. Genentech 17.3.5. Janssen Pharmaceutical 17.3.6. Immunex Corp. 17.3.7. Medac Pharma 17.3.8. Boehringer Ingelheim 17.3.9. Novartis, Biogen 17.3.10. Eli Lilly And Company 17.3.11. Astellas Pharma 17.3.12. Mallinckrodt 17.3.13. Roche 17.3.14. Vertex Pharmaceutical 17.3.15. Genentech 17.3.16. Amgen, Inc. 17.3.17. Merck & Co., Inc. 17.3.18. F. Hoffmann-La Roche Ltd 17.3.19. Sanofi 17.3.20. Celgene Corporation 17.3.21. Gilead Sciences, Inc. 18. Primary Key Insights

About This Report

Report ID 36112
Category Healthcare
Published Date Nov 2019
Updated Date Nov 2020
Contact Us